MAPT and amyloidosis: In such a scenario, a later starting point in an individual's disease course (when the paritcipant has both tau and amyloid pathology) could be associated with an increased rate of decline relative to non-risk groups (as in Figure 2), but may at that stage be a more tau-based process that would not be as impacted by a genetic predisposition toward higher levels of ceramides.